Scholarlink

<p>Ulcerative colitis (UC) is a chronic immune-mediated inflammatory bowel disease. β-Thalassemia minor (TM), a common hemoglobinopathy in Mediterranean populations, is characterized by immune alterations that may overlap with UC pathogenesis. The effect of TM on the clinical course of UC has not been previously investigated. This retrospective observational study compared 25 UC patients with coexisting TM to 72 UC patients without TM. Clinical data, treatment patterns, hospitalization rates, and laboratory parameters including C-reactive protein (CRP) were analyzed. TM patients had significantly lower CRP levels (2.8 vs. 9.4&#xa0;mg/L, <i>p</i> = 0.019), fewer hospitalizations (2 vs. 15 over two years, <i>p</i> &lt; 0.001), and lower rates of anti-TNF and immunomodulator use. All TM patients were managed with mesalazine alone. These preliminary findings suggest that TM may be associated with a milder inflammatory profile in UC patients. Given the retrospective design and limited sample size, prospective studies with validated disease activity measures are warranted.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

β-Thalassemia Minor is Associated with Lower Inflammatory Burden in Ulcerative Colitis: A Pilot Observational Study

  • 期刊论文

  • 发表日期：

    2026年5月30日

查看全文
  • Gokhan Aydin,
  • Hasan Mucahit Ozbas,
  • Ahmet Cumhur Dulger,
  • Burak Kavuklu

摘要

Ulcerative colitis (UC) is a chronic immune-mediated inflammatory bowel disease. β-Thalassemia minor (TM), a common hemoglobinopathy in Mediterranean populations, is characterized by immune alterations that may overlap with UC pathogenesis. The effect of TM on the clinical course of UC has not been previously investigated. This retrospective observational study compared 25 UC patients with coexisting TM to 72 UC patients without TM. Clinical data, treatment patterns, hospitalization rates, and laboratory parameters including C-reactive protein (CRP) were analyzed. TM patients had significantly lower CRP levels (2.8 vs. 9.4 mg/L, p = 0.019), fewer hospitalizations (2 vs. 15 over two years, p < 0.001), and lower rates of anti-TNF and immunomodulator use. All TM patients were managed with mesalazine alone. These preliminary findings suggest that TM may be associated with a milder inflammatory profile in UC patients. Given the retrospective design and limited sample size, prospective studies with validated disease activity measures are warranted.